{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/breast-screening/management/breast-screening/","result":{"pageContext":{"chapter":{"id":"c7eb0bd1-7003-5aef-95f5-80bc5ef56784","slug":"breast-screening","fullItemName":"Scenario: Breast screening","depth":2,"htmlHeader":"<!-- begin field a3087897-52af-4166-a42e-999d7ebf7818 --><h2>Scenario: Breast screening</h2><!-- end field a3087897-52af-4166-a42e-999d7ebf7818 -->","summary":"Covers information on the NHS Breast Screening Programme, to help women make an informed choice.","htmlStringContent":"<!-- begin item 9188f983-af4d-4a6a-bc25-9bb790a3abdc --><!-- begin field 78693f57-4126-4809-8e7f-acbc0155a52a --><p>From age 47 years onwards (Female).</p><!-- end field 78693f57-4126-4809-8e7f-acbc0155a52a --><!-- end item 9188f983-af4d-4a6a-bc25-9bb790a3abdc -->","topic":{"id":"8257a679-f32a-5e83-a761-f385fdd5c0df","topicId":"e5d4d316-9b4d-47e1-9172-8a0c31456fa0","topicName":"Breast screening","slug":"breast-screening","lastRevised":"Last revised in December 2017","chapters":[{"id":"4cec5287-964d-5310-8161-32fd0cba3274","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1249d6b9-91f0-5eda-a49b-332568a0c8ec","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"11e0e9df-e8bb-5231-b2ef-8139d581da21","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"1afda625-3b36-54d1-9cf3-2a2f39d40cde","slug":"changes","fullItemName":"Changes"},{"id":"6c9c99e6-29d0-5848-9ea2-34fc9b7b2160","slug":"update","fullItemName":"Update"}]},{"id":"127c07ef-5bb0-5fec-8ed5-ead9d18a0dbf","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"aa5021a0-174f-5568-8c81-452398f7c7a7","slug":"goals","fullItemName":"Goals"},{"id":"c574242a-936f-5834-9d25-4084193d9f00","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"af1b034f-7a03-5c60-bd11-3193dfa6fe00","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"924962ed-5d65-54c0-a9b3-4ca5fbf7bff6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"efe89c15-560e-5bdd-bfcf-b5f15161afb6","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d0ef4b8d-a9fb-5f0f-8209-75a1fa23a9f4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"8c6b2397-ef01-5a91-8ae2-3a933bd4b635","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"284924e6-a931-562e-8071-64924bcefcfb","slug":"the-nhs-breast-screening-programme","fullItemName":"The NHS Breast Screening Programme"},{"id":"0e715bef-3ed1-519f-ad24-ba590408f8fd","slug":"screening-criteria","fullItemName":"Screening criteria"}]},{"id":"16d62d63-8a53-5db2-a214-fac7cd328395","fullItemName":"Management","slug":"management","subChapters":[{"id":"c7eb0bd1-7003-5aef-95f5-80bc5ef56784","slug":"breast-screening","fullItemName":"Scenario: Breast screening"}]},{"id":"bc5a3ffc-27df-5fbe-940b-c26f85a74511","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"dc299ad5-4d73-5ce1-98e9-11e512a44085","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b40d9ad3-7d31-5868-93a5-d427de589a16","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"152f045f-8083-588a-b344-eb72f3eb8aaa","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d89c3615-f180-5bdf-93e1-f8f35af04c55","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ead385ce-c38b-587d-8806-79f0e9faddc9","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6b46dde2-b89d-571e-8443-3974687d6864","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9a92e46e-5369-5f36-b8ea-1167f1c53b27","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"16d62d63-8a53-5db2-a214-fac7cd328395","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"99d9e165-eeff-52b8-a3bf-a7a66f5fe89e","slug":"information-about-breast-screening","fullItemName":"Information about breast screening","depth":3,"htmlHeader":"<!-- begin field c203d6a0-fe02-4545-9994-4c1a40f12c15 --><h3>What information should I give a woman about breast screening?</h3><!-- end field c203d6a0-fe02-4545-9994-4c1a40f12c15 -->","summary":null,"htmlStringContent":"<!-- begin item 12fed809-bd77-45d6-925a-b7f3a7a2418f --><!-- begin field c33abaab-a08c-4125-b023-732fbc08883c --><p><strong>Inform women about the mammogram procedure, and the benefits and risks of breast screening, so that she can make an informed decision about participation in the programme.</strong></p><ul><li><strong>Give advice on sources of information and support, such as:</strong><ul><li>The Public Health England (PHE) leaflet on <a data-hyperlink-id=\"ec686f14-eaf3-4804-9f4a-a98e00785437\" href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/598584/breast_screening_leaflet.pdf\" target=\"_blank\">NHS breast screening. Helping you decide</a>.</li><li>The NHS Inform (Scotland) information <a data-hyperlink-id=\"a55cd57f-cc96-4a08-8313-a98e00785476\" href=\"https://www.nhsinform.scot/healthy-living/screening/breast-screening/introduction-to-breast-screening\" target=\"_blank\">Introduction to breast screening</a>.</li><li>The NHS leaflet on <a data-hyperlink-id=\"52ca4917-9452-4b14-9483-a98e007854b9\" href=\"https://www.nhs.uk/conditions/breast-cancer-screening/\" target=\"_blank\">Breast cancer screening</a>.</li></ul></li><li><strong>Explain the process of breast screening using mammography (radiography) of each breast.</strong><ul><li>An invitation for breast screening will arrive by post. If the time and place are inconvenient, the appointment can be rearranged. The screening unit may be mobile, hospital-based, or permanently based in a convenient location such as a shopping centre, and the appointment should last about 30 minutes.<ul><li>Advise that women should avoid the use of talcum powder or spray-on deodorant on the day of breast screening as this may affect the mammogram.</li><li>Mammography requires removal of clothes from the top part of the body, including the bra if the woman is wearing one.</li><li>Each breast is placed in turn on the machine and gently but firmly compressed with a flat, clear, plastic plate. Some women find this uncomfortable or painful, as the breasts have to be held firmly in position and pressed to get a good-quality image.</li><li>After screening, women should await contact from the breast screening service about the test results and any follow up required.</li><li>About 1 in 23 women are called back because their mammogram shows that more tests are needed. Most of these women will <em>not</em> have breast cancer.</li></ul></li></ul></li><li><strong>Explore the woman's beliefs and expectations about breast screening, and give information on the possible <a class=\"topic-reference internal-reference\" href=\"/topics/breast-screening/management/breast-screening/#benefits-harms\">benefits and harms</a>:</strong><ul><li>Benefits include:<ul><li>Reduction in mortality — breast screening detects breast cancers and saves lives, with the greatest reduction in mortality seen in women aged 50–70 years.</li><li>More breast-conserving treatment due to an increase in the early detection of breast cancer.</li></ul></li><li>Harms include:<ul><li>Over-diagnosis (the detection of breast cancers through screening that would not have been diagnosed without screening in the woman's lifetime, and would not have been life-threatening), which leads to unnecessary treatment.</li><li>False-positive mammograms leading to unnecessary further investigations (clinical examination, further mammography, breast ultrasound, and fine-needle aspiration and/or biopsy).</li><li>False reassurance due to missed cancer and incorrect diagnosis.</li><li>Pain and discomfort due to mammography.</li><li>Psychological distress such as anxiety or uncertainty, for example following a false-positive result.</li><li>Radiation exposure, which may increase the risk of breast cancer.</li></ul></li></ul></li><li><strong>Explain to women with breast implants that:</strong><ul><li>Mammography is the most accurate method of early detection of breast cancer although some of the breast tissue in women with implants is obscured by the radiopaque implant during routine mammography.<ul><li>Detection of breast cancer at an early stage is therefore more difficult due to the impaired view of the breast tissue.</li><li>Additional screening images may be taken at the initial mammography appointment, to visualise as much breast tissue as possible and improve cancer detection rates. This may be performed at a hospital screening unit.</li><li>The NHS leaflet on <a data-hyperlink-id=\"ddc99f09-ea0a-4ef2-a8c2-a98e007854d4\" href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/441256/breast-implants-breast-screening.pdf\" target=\"_blank\">Breast implants and breast screening</a> may be helpful.</li></ul></li></ul></li><li><strong>If a woman has a physical disability that may make breast screening difficult,</strong> such as limited mobility in the upper body or she cannot support her upper body unaided<strong>:</strong><ul><li>Explain that:<ul><li>The woman has to be positioned carefully and hold that position for several seconds.</li><li>If a mammogram is not technically possible at a particular time, the woman should still remain in the call and recall programme, as any change in her condition or in screening procedures may allow for screening at a later date.</li></ul></li><li>Advise her to contact the local breast screening service to get advice on whether mammography is technically possible, and where the best place would be to attend for a mammogram (such as a static rather than a mobile unit).</li><li>Contact details are available at:<ul><li>England — <a data-hyperlink-id=\"17e571a7-399d-4d01-97ba-a98e007854ff\" href=\"https://www.nhs.uk/Service-Search/Breast%20screening%20services/LocationSearch/325\" target=\"_blank\">NHS breast screening services</a>.</li><li>Wales — <a data-hyperlink-id=\"a54c6127-dca1-469b-a00e-a98e00785609\" href=\"http://www.breasttestwales.wales.nhs.uk/contact-us\" target=\"_blank\">Breast Test Wales screening centres</a>.</li><li>Scotland — <a data-hyperlink-id=\"be6f63d9-341e-466a-b130-a98e0078562c\" href=\"http://www.nsd.scot.nhs.uk/services/screening/breastscreening/screeningcentres.html\" target=\"_blank\">Scottish breast screening centres</a>.</li><li>Northern Ireland — <a data-hyperlink-id=\"1cec11a0-51c5-4d80-8e0c-a98e0078569e\" href=\"http://www.cancerscreening.hscni.net/Location_contact_details_of_units.htm\" target=\"_blank\">cancerscreening.hscni.net</a>.</li></ul></li></ul></li><li><strong>If a woman has a learning disability or lacks <a class=\"topic-reference internal-reference\" href=\"/topics/breast-screening/management/breast-screening/#consent-issues\">mental capacity</a> to make an informed decision about breast screening:</strong><ul><li>Assess whether she has fluctuating mental capacity, in which case, the decision about participating in screening should be delayed until the woman is able to decide for herself.</li><li>If she has ongoing lack of mental capacity to make an informed decision, make a best interests decision on her behalf.</li><li>The NHS leaflet on <a data-hyperlink-id=\"9fb977be-99a8-4ec1-8b55-a98e007856c6\" href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/441270/easy-guide-breast-screening.pdf\" target=\"_blank\">An Easy Guide to Breast Screening</a> and the British Medical Association (BMA) <a data-hyperlink-id=\"c24a613b-cc3b-4073-931e-a98e00785703\" href=\"https://www.bma.org.uk/advice/employment/ethics/mental-capacity/mental-capacity-toolkit\" target=\"_blank\">Mental capacity toolkit</a> may be helpful sources of information.</li></ul></li></ul><!-- end field c33abaab-a08c-4125-b023-732fbc08883c --><!-- end item 12fed809-bd77-45d6-925a-b7f3a7a2418f -->","subChapters":[{"id":"24e6a33e-a7a8-5d04-859b-a36309ff82a0","slug":"benefits-harms","fullItemName":"Benefits and harms","depth":4,"htmlHeader":"<!-- begin field 0d0c62b5-b164-4839-9e47-a84600bcc283 --><h4>What are the benefits and harms?</h4><!-- end field 0d0c62b5-b164-4839-9e47-a84600bcc283 -->","summary":null,"htmlStringContent":"<!-- begin item 48b6375f-2768-4bce-8669-a84600bcc036 --><!-- begin field 1eae9947-b8a1-40a5-95e1-a84600bcc283 --><p><strong>There is conflicting opinion in the literature on the relative benefits and harms of breast cancer screening, and trial estimates vary widely for each parameter </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">Marmot, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">Barratt, 2015</a>]<strong>.</strong></p><h5>Breast cancers detected</h5><ul><li>From 50–70 years of age, screening prevents about 1 breast cancer death for every 200 women screened regularly. Since UK women are offered 7 screens between age 50 and 70, the equivalent of about 1 death prevented per 1400 screens [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">PHE, 2017b</a>].</li><li>Before age 50, about 15 out of every 200 women screened will be asked to return for more tests, but on average only about one of them will be found to have breast cancer. Around 1 in every 200 screens before age 50 is likely to result in a breast cancer being found [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">PHE, 2017b</a>].</li><li>After age 70, only about 7 out of every 200 screens results in the woman being asked to return for more tests, but on average about two of them will be found to have breast cancer. Around 2 in every 200 screens after age 70 is likely to result in a breast cancer being found [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">PHE, 2017b</a>].</li><li>In 2015–16 in England [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">NHS Digital, 2017</a>]:<ul><li>A total of 18,320 women aged 45 and over had cancers detected by the screening programme, which represents a rate of 8.5 cases per 1,000 women screened.</li><li>Of all women with cancers detected, 41.2% (7,543 women) had invasive but small cancers (less than 15mm in diameter) which are usually too small to detect by palpation on clinical examination.</li><li>Detection rates were lowest for women aged 45-49 (6.2 women with cancer detected per 1,000 women screened). The detection rate was highest amongst women over 70 years (14.6 women per 1,000 women screened).</li></ul></li></ul><h5>Reduced mortality</h5><ul><li>The Independent UK Panel on Breast Cancer Screening performed a meta-analysis of 11 randomized trials, and found the relative risk of breast cancer mortality for women invited to screening compared with controls not invited was 0.80, which is a relative risk reduction of 20%. This equates to [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">Marmot, 2012</a>]:<ul><li>For every 10,000 UK women aged 50 years invited to screening for the next 20 years, 43 deaths from breast cancer would be prevented.</li><li>One breast cancer death prevented for every 235 women invited for screening.</li><li>One breast cancer death prevented for every 180 women who attend screening.</li><li>About 1300 breast cancer deaths prevented every year.</li></ul></li><li>A Cochrane systematic review of seven randomized trials (n = 600,000) examined the effect of breast screening mammography on mortality and morbidity in women aged 39–74 years [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">Gotzsche, 2013</a>]:<ul><li>Four trials with suboptimal randomization showed a significant reduction in breast cancer mortality with a relative risk of 0.75.</li><li>It concluded, however, that breast cancer mortality was an unreliable outcome that was biased in favour of screening, mainly due to the differential misclassification of cause of death.</li><li>It also notes that due to substantial advances in treatment and greater breast cancer awareness since the trials in the meta-analysis were carried out, it is likely that the absolute effect of screening is smaller than the included trials suggest.</li></ul></li><li>Expert opinion in a review article notes that screening detects mainly slow-growing cancers, and over-diagnosed breast cancer has an excellent prognosis (97% survival after 10 years). A highly selected population (those who attend screening) combined with the expected natural course of the pathology detected will give a very good outcome, unrelated to whether or not screening makes a difference [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">Jørgensen and Gøtzsche, 2010</a>].</li></ul><h5>Increased breast-conserving treatment</h5><ul><li>The Advisory Committee on Breast Cancer Screening estimated that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">Advisory Committee on Breast Cancer Screening, 2006</a>]:<ul><li>Seven in every 10 women diagnosed with breast cancer during screening had breast-conserving therapy compared with 5 in every 10 women outside the screening programme.</li><li>One in every eight women diagnosed with breast cancer through screening will be spared a mastectomy due to early detection.</li></ul></li></ul><h5>Over-diagnosis (over-detection) leading to unnecessary treatment</h5><ul><li>Over-diagnosis refers to the detection of low-risk or non-progressing breast cancers through screening that would not have been diagnosed without screening, and would not have been life-threatening [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">Barratt, 2015</a>].<ul><li>Once diagnosed through screening, treatment is recommended to all women to reduce the risks of recurrence and breast cancer mortality, as it is not possible to distinguish non-progressive from progressive disease, due to the lack of reliable prognostic markers.</li><li>Breast cancer treatments such as radiotherapy, chemotherapy, and hormonal treatments may have associated risks.</li></ul></li><li>The Independent UK Panel on Breast Cancer Screening meta-analysis of three trials found that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">Marmot, 2012</a>]:<ul><li>For every 10,000 UK women aged 50 years invited to screening for the next 20 years, 129 cases of breast cancer (invasive and non-invasive) would be over-diagnosed, which equates to 19% of breast cancers in this group of women.</li><li>Of the 307,000 women aged 50–52 years invited to begin screening each year, just over 1% would have an over-diagnosed cancer in the next 20 years.</li><li>The Panel acknowledged that these figures are based on limited trial data.</li></ul></li></ul><h5>False-positive mammograms</h5><ul><li> In 2009–2010, more than 2.24 million women aged 50–73 years in England were invited to take part in the breast screening programme, of whom 73% attended. Of these, 64,104 women (4.4%) were recalled for assessment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">NHS Information Centre, 2011</a>].<ul><li>Of those recalled, 42% had cytology and/or a core biopsy, 2.7% had an open biopsy.</li><li>81% did not have breast cancer and had a false-positive mammogram. These women would not have required further assessment had they not attended for screening.</li></ul></li><li>In 2015–16 in England, of women aged 45 and over attending for the first time, 7.6% were referred for further assessment following their initial mammogram [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">NHS Digital, 2017</a>].</li><li>A systematic review of seven studies concluded that the experience of having a false-positive screening mammogram can cause breast cancer-specific psychological distress that may persist for up to 3 years, and reduce the likelihood that women will return for their next round of mammography screening compared with women with normal mammogram results [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">Bond, 2013</a>].<ul><li>The level of distress was associated with the degree of invasiveness of subsequent assessment.</li><li>There were, however, limitations in the design of the included observational studies, and significant heterogeneity was noted which precluded a meta-analysis.</li></ul></li><li>PHE also notes that recall for assessment such as repeat mammography and/or ultrasound is associated with significant anxiety, particularly as most women have had no previous indication of a breast problem [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">PHE, 2016</a>].</li></ul><h5>False reassurance</h5><ul><li>There is limited evidence from a Dutch study to suggest that, in women who have been previously screened for breast cancer, false reassurance has no significant effect in terms of delaying presentation of symptoms or signs to primary care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">de Gelder et al, 2008</a>].</li><li>A Canadian systematic review of 16 qualitative studies (n = 690) examining women's experiences of inaccurate breast cancer screening results found that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">DeJean, 2016</a>]:<ul><li>Some women who had experienced false-negative results lost confidence in the screening process, but recognized that some cancers were detected through mammography, and were willing to see themselves as exceptions to an otherwise beneficial service at a population level.</li><li>All women who had experienced a false-negative test result indicated that they would continue to participate in mammography screening.</li></ul></li></ul><h5>Pain</h5><ul><li>A Cochrane systematic review of seven randomized controlled trials (n = 1671) that studied interventions to reduce or relieve pain and discomfort associated with screening mammography cited that up to 35% of women report pain during and after the mammogram procedure [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">Miller et al, 2008</a>].</li><li>A systematic review of 20 studies on the effect of mammography pain on participation in breast cancer screening found that 25–46% of non-attendees cited pain at previous mammogram as the reason for non-attendance at subsequent screening appointments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">Whelehan, 2013</a>].</li></ul><h5>Radiation-induced breast cancer</h5><ul><li>There is limited evidence of a small risk of radiation-induced breast cancer, with estimates averaging 0.07 per 1000 women screened at 50–70 years of age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">Advisory Committee on Breast Cancer Screening, 2006</a>].</li></ul><!-- end field 1eae9947-b8a1-40a5-95e1-a84600bcc283 --><!-- end item 48b6375f-2768-4bce-8669-a84600bcc036 -->","subChapters":[]},{"id":"c971c7f8-ba34-5f16-9269-b5bfbf6a996c","slug":"consent-issues","fullItemName":"Consent issues","depth":4,"htmlHeader":"<!-- begin field eb382bb1-0885-4231-99c9-a84600bcdc1b --><h4>Consent issues</h4><!-- end field eb382bb1-0885-4231-99c9-a84600bcdc1b -->","summary":null,"htmlStringContent":"<!-- begin item 04e5fc6e-dc24-40a1-87e9-a84600bcd98e --><!-- begin field df42d971-7912-43fd-abe5-a84600bcdc1b --><ul><li><strong>If a woman lacks mental capacity to make an informed decision about undergoing breast screening,</strong> take into account the following issues when discussing with her family, close friend(s), or carer to enable a 'best interests' decision to be reached:<ul><li>The woman's risk of developing breast cancer. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/breast-cancer-managing-fh/\">Breast cancer - managing FH</a> for more information.</li><li>What the screening process involves.</li><li>What further tests or treatment she might need if she received an abnormal result.</li><li>Whether she has expressed views in the past about screening or whether she would want to know if she had a disease.</li><li>Whether she has declined screening in the past.</li><li>What the woman would have wanted herself.</li><li>That permanent mental incapacity is not usually a barrier to screening.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">BMA, 2016</a>] </p><!-- end field df42d971-7912-43fd-abe5-a84600bcdc1b --><!-- end item 04e5fc6e-dc24-40a1-87e9-a84600bcd98e -->","subChapters":[]},{"id":"da2c86dc-af19-54c9-8e3b-7e9f81975d19","slug":"basis-for-recommendation-447","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 21edbd73-253b-42f7-ae8a-751bbe094376 --><h4>Basis for recommendation</h4><!-- end field 21edbd73-253b-42f7-ae8a-751bbe094376 -->","summary":null,"htmlStringContent":"<!-- begin item 447101f6-8d23-4791-a0e9-2432403d6f44 --><!-- begin field 02355e81-02e6-461d-90bc-41fd6adecf7c --><p>The recommendations on management are largely based on the Public Health England NHS Breast Screening Programme documents <em>Clinical guidance for breast cancer screening assessment</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">PHE, 2016</a>], <em>Screening women with breast implants</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">PHE, 2017a</a>], and <em>The AgeX Trial. Trial of extending the age range of breast screening to include some women aged under 50 or over 70</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">PHE, 2017b</a>], the NHS Digital publication <em>Breast screening programme: England, 2015–16</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">NHS Digital, 2017</a>], the Cochrane systematic reviews <em>Interventions for relieving the pain and discomfort of screening mammography</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">Miller et al, 2008</a>] and <em>Screening for breast cancer with mammography</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">Gotzsche, 2013</a>], systematic reviews on the effect of false-positive screening results [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">Bond, 2013</a>], inaccurate screening results [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">DeJean, 2016</a>], and mammography pain [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">Whelehan, 2013</a>]; and expert opinion in review articles on the benefits and harms of breast screening [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">Marmot, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">Barratt, 2015</a>].</p><ul><li>The Independent UK Panel on Breast Cancer Screening noted that different meta-analyses in the literature are based on different trials, durations of follow-up, definitions of outcome, and methods of analysis, and therefore estimates of harms and benefits from breast screening vary widely [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">Marmot, 2012</a>].</li><li>The Cochrane systematic review on mammography screening concluded that the benefits of universal mammography are 'uncertain' and it leads to over-diagnosis and unnecessary interventions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">Gotzsche, 2013</a>].</li><li>The Cochrane systematic review on pain and discomfort analyzed seven randomized controlled trials (RCTs, n = 1671) as single studies, and found that giving women information before the procedure may reduce pain and discomfort [<a class=\"bibliography-reference internal-reference\" href=\"/topics/breast-screening/references/\">Miller et al, 2008</a>].</li></ul><!-- end field 02355e81-02e6-461d-90bc-41fd6adecf7c --><!-- end item 447101f6-8d23-4791-a0e9-2432403d6f44 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}